Diazepam Stada (Diazepam)

Diazepam Stada is prescribed for several central nervous system conditions where its anxiolytic, anticonvulsant, muscle‑relaxant, and sedative properties are beneficial.

• Management of generalized anxiety disorder and other anxiety‑related conditions.
• Adjunctive therapy for certain seizure disorders, including status epilepticus.
• Relief of acute muscle spasm associated with musculoskeletal injuries.
• Treatment of symptoms associated with alcohol withdrawal syndrome.
• Short‑term sedation prior to medical procedures when indicated.

Side effects of diazepam may vary in frequency and severity, reflecting its central nervous system activity.

Common

• Drowsiness or fatigue
• Dizziness or light‑headed feeling
• Impaired coordination or gait instability
• Memory disturbances, such as difficulty recalling recent events

Serious

• Respiratory depression, especially when combined with other depressants
• Severe hypotension or cardiovascular collapse
• Paradoxical reactions including agitation, aggression, or hallucinations
• Dependence, withdrawal syndrome, or tolerance with prolonged use

Clinicians should evaluate patient‑specific factors before initiating diazepam therapy to minimize risks.

• Assess for a history of respiratory disorders, such as chronic obstructive pulmonary disease or sleep apnea.
• Use caution in patients with hepatic impairment, as metabolism may be reduced.
• Evaluate for potential dependence, especially in individuals with substance‑use disorders.
• Avoid abrupt discontinuation after prolonged therapy to prevent withdrawal symptoms.
• Consider dose adjustment in elderly patients due to increased sensitivity.
• Review pregnancy and lactation status, as safety data are limited.

Diazepam can interact with a range of medications, altering its efficacy or safety profile.

Avoid

• Concomitant use with other central nervous system depressants (e.g., opioids, barbiturates, alcohol) due to additive sedation and respiratory risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) which can increase diazepam plasma concentrations.
• CYP2C19 inhibitors (e.g., fluoxetine, omeprazole) that may elevate active metabolite levels.

Use with caution

• CYP3A4 inducers (e.g., carbamazepine, rifampin) which may reduce therapeutic effect.
• Other benzodiazepines or sedative‑hypnotics, requiring dose adjustments.
• Antidepressants or antipsychotics that may potentiate central effects.